Earnings Scheduled For November 14, 2024
Adaptimmune Therapeutics Plc (ADAP) Q3 2024 Earnings Call Transcript Summary
The Oncology Bet Is Already Paying Off For Pfizer
Adaptimmune GAAP EPS of -$0.01 Beats by $0.07, Revenue of $40.9M Beats by $20.41M
Here's the Major Earnings Before the Open Tomorrow
Adaptimmune to Engage in Restructuring; 33% Headcount Reduction